What's happening
This bill requires New York's health department to seek federal guidance on Medicaid coverage for FDA-approved prescription digital therapeutics treating substance and opioid use disorders.
Why it matters
Expands treatment options for vulnerable populations. By seeking Medicaid coverage for FDA-approved prescription digital therapeutics (PDTs), the bill could help individuals with substance and opioid use disorders—especially those facing barriers to in-person care—access new, evidence-based remote treatments.
Addresses urgent needs worsened by the pandemic. The legislation responds to increased relapse risks due to COVID-19-related social distancing, aiming to ensure continuity of care for people unable to attend traditional therapy sessions.
Could set a precedent for digital health innovation. If New York secures federal support for PDT coverage, it may encourage broader acceptance and reimbursement of digital therapeutics, potentially shaping future Medicaid policy and access nationwide.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
New York State Department of Health
The bill would require the department to request federal guidance within 30 days on whether Medicaid federal matching funds are available for certain FDA-approved prescription digital therapeutics.
Medicaid enrollees with substance use and opioid use disorders
The requested guidance would address a potential coverage and payment pathway for software-based treatments for their conditions, without itself guaranteeing coverage.
Prescription digital therapeutics manufacturers
Federal guidance could clarify whether the state can claim federal funding for coverage of and payment for their FDA-approved treatments for substance use and opioid use disorders.
Substance use treatment providers
The bill would seek clarity on Medicaid funding for prescription software-based therapies that can provide remote treatment for their patients.
Headline styles
Expand Digital Therapy Coverage
Plain English, a few words. Used as the page title.
Sponsors
1 Co-sponsor
History
- Approval memo.102
- Signed chap.824
- Delivered to governor
- Returned to senate
- Passed assembly
- Ordered to third reading rules cal.445
- Substituted for A3642
- Referred to ways and means
- Delivered to assembly
- Passed senateVote 61–0
- Advanced to third reading
- 2nd report cal.
Show 3 earlier actions
- 1st report cal.514
- Referred to health
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Expand Digital Therapy Coverage
Assembly Floor Calendar · Sponsor Linda Rosenthal
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
559
2021-2022 Regular Sessions
IN SENATE (Prefiled)
January 6, 2021
Introduced by Sen. HARCKHAM -- read twice and ordered printed, and when printed to be committed to the Committee on Health
AN ACT in relation to determining whether the state can claim federal financial participation for coverage of and payment for certain prescription digital therapeutics
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Legislative finding and declaration. New Yorkers in recovery for substance and opioid use disorders and in treatment for mental health conditions are losing access to in-person treatment under the state's "stay at home" and social distancing orders as part of coronavirus pandemic mitigation efforts. In recent news reports, experts warn that the coronavirus pandemic may be "a national relapse trigger" for individuals in treatment for alcohol, cocaine, methamphetamine, marijuana, and heroin addiction. Prescription Digital Therapeutics (PDTs) are new, software-based disease treatments designed to directly treat disease, tested for safety and efficacy in randomized clinical trials, evaluated by the FDA, and prescribed by healthcare providers. These therapies are designed and tested much like traditional prescription drugs with one distinction: rather than swallowing a pill or taking an injection, patients are treated with software. Certain PDTs provide clinicians and patients with evidence-based remote treatment modalities to treat substance and opioid use disorders, mental health, and other diseases and conditions. However, there is no clear statutory benefit category to allow Medicaid coverage for PDTs. In light of the promise of PDTs for the treatment of patients with substance use and opioid use disorders during the coronavirus pandemic, this legislation would require that the New York state department of health seek guidance from the Centers for Medicare and Medicaid Services relative to a coverage
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD01006-01-1
S. 559 2
and reimbursement pathway for PDTs, in order to accelerate access to such therapies for enrollees.
§ 2. No later than 30 days from the effective date of this section, the New York state department of health shall request guidance from the Centers for Medicare and Medicaid Services to determine whether the state can claim federal financial participation for coverage of and payment for certain prescription digital therapeutics approved by the food and drug administration to treat substance use and opioid use disorders.
§ 3. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act in relation to determining whether the state can claim federal financial participation for coverage of and payment for certain prescription digital therapeutics
Purpose
This bill seeks to have prescription digital therapeutics covered by Medicaid.
Summary of specific provisions
Section one contains the legislative findings.
Section two directs the New York State Department of Health to request guidance from the Centers for Medicare and Medicaid Services regarding coverage of digital therapeutics.
Section three establishes the effective date.
Justification
Prescription digital therapeutics (PDTs) are therapeutic interventions that use software programs to help prevent, manage or treat a medical disorder or disease. These treatments are prescribed by healthcare professionals, have been tested in randomized clinical trials and have received approval by the U.S. Food and Drug Administration. PDTs are being increasingly used for the treatment of opioid use disorders as they allow patients to use software to easily track their cravings and triggers in real time, complete cognitive behavioral therapy lessons and participate in contingency management interventions.The information gained through this software is available to the clinician, allowing them to modify treatment to best fit the needs of the patient.
Trials have shown PDTs to be highly successful in increasing treatment attendance and retention rates. However, these therapies are not currently covered by Medicaid, and therefore access to them remains limited. This legislation would request guidance from the Centers for Medicare and Medicaid Services regarding coverage of digital therapeu- tics, allowing more individuals the opportunity to have these programs incorporated into their treatment.
Legislative history
2020: S8316 referred to Health; same as A10385 (Rosenthal L) referred to health
Fiscal implications
Undetermined.
Effective date
This act shall take effect immediately.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.